{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:46:38Z","timestamp":1792014398266,"version":"4.4.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"Abstract<\/jats:title>\n \n Objective<\/jats:title>\n Polypharmacy has been associated with morbidity and mortality in patients with cancer. Data about polypharmacy among patients with ovarian cancer are limited. The primary objective of this study was to evaluate polypharmacy in a cohort of patients with ovarian cancer and to assess the evolution of polypharmacy from initial presentation to 2 years posttreatment. A secondary objective was to evaluate differences in polypharmacy between a subset of patients primarily treated in our comprehensive cancer center (CCC) and our safety net hospital (SNH).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Women treated for ovarian cancer between January 1, 2011, and December 31, 2016, were included. Data were abstracted from the electronic medical record. Medication safety was assessed using the established Anticholinergic Burden (ACB) scale and the Beers criteria. Statistical analyses were performed using paired t tests and Cox proportional hazards models, with significance set at p &lt; .05.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study included 152 patients. The majority of patients had high-grade serous carcinoma. Hypertension was the most common medical problem. The mean number of medications at the time of diagnosis was 3.72. Paired testing demonstrated significant patient-level increases in the number medications at 2 years following initial diagnosis (4.16 vs. 7.01, p &lt; .001). At the CCC, 47.4% of patients met criteria for polypharmacy at diagnosis compared with 19.4% at the SNH (p &lt; .001). By 2 years postdiagnosis, 77.6% of patients at the CCC met criteria for polypharmacy compared with 43.3% at the SNH (p = .001). The use of any medications on the ACB scale (p &lt; .001) increased significantly between initial diagnosis and 2 years for the entire population. Polypharmacy was not a significant predictor of overall survival.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Polypharmacy worsens as women go through ovarian cancer treatment. Both at initial presentation and at 2 years postdiagnosis, rates of polypharmacy were higher at the CCC. Polypharmacy did not have an effect on survival in this cohort.<\/jats:p>\n <\/jats:sec>\n \n Implications for Practice<\/jats:title>\n Awareness of escalating numbers of medications and potentially adverse interactions is crucial among women with ovarian cancer, who are at high risk for polypharmacy.<\/jats:p>\n <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0807","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T18:05:37Z","timestamp":1554487537000},"page":"1201-1208","source":"Crossref","is-referenced-by-count":8,"title":["Polypharmacy in Patients with Ovarian Cancer"],"prefix":"10.1093","volume":"24","author":[{"given":"Sean","family":"Oldak","sequence":"first","affiliation":[{"name":"Miller School of Medicine, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Ioannou","sequence":"additional","affiliation":[{"name":"Miller School of Medicine, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Kamath","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Huang","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"George","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Slomovitz","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Schlumbrecht","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"key":"2021122507523114300_onco12934-bib-0001","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jclinepi.2012.02.018","article-title":"Polypharmacy cutoff and outcomes: Five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes","volume":"65","author":"Gnjidic","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"2021122507523114300_onco12934-bib-0002","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00520-014-2171-x","article-title":"Prevalence and factors associated with polypharmacy in older people with cancer","volume":"22","author":"Turner","year":"2014","journal-title":"Support Care Cancer"},{"key":"2021122507523114300_onco12934-bib-0003","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jgo.2012.02.005","article-title":"Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer","volume":"3","author":"Prithviraj","year":"2012","journal-title":"J Geriatr Oncol"},{"key":"2021122507523114300_onco12934-bib-0004","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2710.2007.00815.x","article-title":"Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management","volume":"32","author":"Sokol","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"2021122507523114300_onco12934-bib-0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1078155208090624","article-title":"Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: Questionnaire validation","volume":"14","author":"Hanigan","year":"2008","journal-title":"J Oncol Pharm Pract"},{"key":"2021122507523114300_onco12934-bib-0006","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/ggi.12241","article-title":"Polyphamacy and health outcomes among older adults discharged from the hospital: Results from the CRIME study","volume":"15","author":"Sganga","year":"2015","journal-title":"Geriatr Gerontol Int"},{"key":"2021122507523114300_onco12934-bib-0007","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jgo.2014.04.002","article-title":"Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy","volume":"5","author":"Popa","year":"2014","journal-title":"J Geriatr Oncol"},{"key":"2021122507523114300_onco12934-bib-0008","first-page":"211","article-title":"The impact of polypharmacy on patient outcomes in older adults with cancer","volume":"23","author":"Nightingale","year":"2017","journal-title":"Cancer J"},{"key":"2021122507523114300_onco12934-bib-0009","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.leukres.2014.06.018","article-title":"The prognostic importance of polypharmacy in older adults treatment with acute myelogenous leukemia (AML)","volume":"38","author":"Elliot","year":"2014","journal-title":"Leuk Res"},{"key":"2021122507523114300_onco12934-bib-0010","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/annonc\/mdi368","article-title":"Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: A GINECO study","volume":"16","author":"Freyer","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122507523114300_onco12934-bib-0011","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00228-010-0940-0","article-title":"Prescribed drug-utilization and polypharmacy in a general population in Greece: Association with sociodemographic, health needs, health-services utilization, and lifestyle factors","volume":"67","author":"Pappa","year":"2011","journal-title":"Eur J Clinc Pharmacol"},{"key":"2021122507523114300_onco12934-bib-0012","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1177\/0898264315569455","article-title":"Ethnic differences in geriatric conditions and diabetes complications among older, insured adults with diabetes: The Diabetes & Aging Study","volume":"27","author":"Karter","year":"2015","journal-title":"J Aging Health"},{"key":"2021122507523114300_onco12934-bib-0013","author":"Aging Brain Program of the Indiana University Center of Aging Research","year":"2015"},{"key":"2021122507523114300_onco12934-bib-0014","first-page":"2019","article-title":"American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults","author":"Fick","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"2021122507523114300_onco12934-bib-0015","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.286.22.2823","article-title":"Potentially inappropriate medication use in the community-dwelling elderly: Findings from the 1996 Medical Expenditure Panel Survey","volume":"286","author":"Zhan","year":"2001","journal-title":"JAMA"},{"key":"2021122507523114300_onco12934-bib-0016","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jpainsymman.2014.03.008","article-title":"Polypharmacy in patients with advanced cancer and pain: A European cross-sectional study of 2282 patients","volume":"48","author":"Kotlinska-Lemieszek","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"2021122507523114300_onco12934-bib-0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11912-018-0686-x","article-title":"Prevalence and risk of polypharmacy among elderly patients receiving chemotherapy in an ambulatory oncology setting","volume":"20","author":"Goh","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"2021122507523114300_onco12934-bib-0018","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jgo.2015.05.001","article-title":"Drug-related problems in elderly patients with cancer receiving outpatient chemotherapy","volume":"6","author":"Yeoh","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"2021122507523114300_onco12934-bib-0019","doi-asserted-by":"crossref","first-page":"795","DOI":"10.21873\/anticanres.11379","article-title":"Polypharmacy in older patients \u226570 years receiving palliative radiotherapy","volume":"37","author":"Nieder","year":"2017","journal-title":"Anticancer Res"},{"key":"2021122507523114300_onco12934-bib-0020","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ygyno.2016.01.012","article-title":"The influence of polypharmacy on grade III\/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer","volume":"140","author":"Woopen","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2021122507523114300_onco12934-bib-0021","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/j.1475-6773.2012.01394.x","article-title":"Racial\/ethnic disparities in health and health care among U.S. adolescents","volume":"47","author":"Lau","year":"2012","journal-title":"Health Serv Res"},{"key":"2021122507523114300_onco12934-bib-0022","first-page":"1","article-title":"Surveillance of health status in minority communities - Racial and Ethnic Approaches to Community Health Across the U.S. (REACH U.S.) risk factor survey, United States, 2009","volume":"60","author":"Liao","year":"2011","journal-title":"MMWR Surveill Summ"},{"key":"2021122507523114300_onco12934-bib-0023","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1476-072X-11-48","article-title":"Medication deserts: Survey of neighborhood disparities in availability of prescription medications","volume":"11","author":"Amstislavski","year":"2012","journal-title":"Int J Health Geogr"},{"key":"2021122507523114300_onco12934-bib-0024","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2146\/ajhp150872","article-title":"Evaluation of racial and socioeconomic disparities in medication pricing and pharmacy access and services","volume":"74","author":"Chisholm-Burns","year":"2017","journal-title":"Am J Health Syst Pharm"},{"key":"2021122507523114300_onco12934-bib-0025","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM200004063421406","article-title":"\u201cWe don't carry that\u201d\u2014Failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics","volume":"342","author":"Morrison","year":"2000","journal-title":"N Engl J Med"},{"key":"2021122507523114300_onco12934-bib-0026","first-page":"237","article-title":"Disparities in outpatient antidepressant prescribing patterns and determinants of resource utilization at a tertiary care cancer center","volume":"7","author":"Lal","year":"2009","journal-title":"J Support Oncol"},{"key":"2021122507523114300_onco12934-bib-0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160738","article-title":"Disparities in depressive symptoms and antidepressant treatment by gender and race\/ethnicity among people living with HIV in the United States","volume":"11","author":"Bengtson","year":"2016","journal-title":"PLoS One"},{"key":"2021122507523114300_onco12934-bib-0028","first-page":"155","article-title":"Racial and ethnic disparities in antidepressant use","volume":"11","author":"Chen","year":"2008","journal-title":"J Ment Health Policy Econ"},{"key":"2021122507523114300_onco12934-bib-0029","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1071\/PY10099","article-title":"Medicine use of elderly Chinese and Vietnamese immigrants and attitude to home medicines review","volume":"18","author":"White","year":"2012","journal-title":"Aust J Prim Health"},{"key":"2021122507523114300_onco12934-bib-0030","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/IGC.0b013e31820fa24a","article-title":"Complementary and alternative medicine use among women receiving chemotherapy for ovarian cancer in 2 patient populations","volume":"21","author":"Helpman","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"2021122507523114300_onco12934-bib-0031","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.regg.2013.10.004","article-title":"Quality of life in the elderly on polymedication and with multiple morbidities","volume":"49","author":"Naveiro-Rilo","year":"2014","journal-title":"Rev Esp Geriatr Gerontol"},{"key":"2021122507523114300_onco12934-bib-0032","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1007\/s00520-018-4281-3","article-title":"Pharmacist-led medication assessment and deprescribing intervention for older adults with cancer and polypharmacy: A pilot study","volume":"26","author":"Whitman","year":"2018","journal-title":"Support Care Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0807","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0807","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/9\/1201\/41917802\/oncolo_24_9_1201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/9\/1201\/41917802\/oncolo_24_9_1201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:53:48Z","timestamp":1640418828000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/9\/1201\/6439261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,4,5]]},"published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0807","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9,1]]},"published":{"date-parts":[[2019,4,5]]}}}